Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pinacidil Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC9 known ✓ | O60706 | 8/20 | 1.00 |
| ▸ | KCNJ11 known ✓ | Q14654 | 8/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | NFKB1 | P19838 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 1.00 |
| ▸ | NAMPT | P43490 | 9/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R)-Pinacidil SCHEMBL29484626 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL9260276 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL9351684 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Pinacidil Anhydrous SCHEMBL65787 | 1.00 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9456841 | 0.84 | ABCC9 (0.73) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9298614 | 0.84 | KCNJ11 (0.72) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL9298619 | 0.84 | KCNJ11 (0.72) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Naminidil SCHEMBL1650535 | 0.83 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| Naminidil SCHEMBL6375460 | 0.83 | ABCC9 (1.00) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6369125 | 0.81 | ABCC9 (0.68) | ABCC9KCNJ11CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0306192-B1 | PERMEATION ENHANCEMENT COMPOSITIONS | ELI LILLY AND COMPANY (US) | 1992-05-27 | — | — | EP | claimed |
| EP-2576778-B1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN RODENTS | UNIV KYOTO (JP) | 2017-08-09 | — | — | EP | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-20100113379-A1 | cAMP DEPENDENT INDUCTION OF AUTOPHAGY | RUBINSZTEIN DAVID | 2010-05-06 | — | — | US | disclosed |
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | ALBERT EINSTEIN COLLEGE OF MEDICINE, INC. | 2009-01-08 | — | — | US | disclosed |
| WO-2008099175-A1 | CAMP DEPENDENT INDUCTION OF AUTOPHAGY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2008-08-21 | — | — | WO | disclosed |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | DARA BIOSCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-5532248-A | O-aryl,O-alkyl, and O-alkenyl-macrolides having immunosuppressive activity | MERCK CO., INC. (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0542802-B1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND 5-ALPHA-REDUCTASE INHIBITORS | UPJOHN CO (US) | 1996-03-06 | — | — | EP | disclosed |
| WO-1995009857-A1 | O-ARYL, O-ALKYL, O-ALKENYL AND O-ALKYNYL-MACROLIDES HAVING IMMUNOSUPPRESSIVE ACTIVITY | MERCK & CO., INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-5349061-A | O-heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides having immunosuppressive activity | MERCK & CO., INC. (US) | 1994-09-20 | — | — | US | disclosed |
| EP-0405525-B1 | Novel cyanoguanidine derivatives | KANEBO LTD (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-5344925-A | Autoimmune diseases; infections; organ transplants | MERCK & CO., INC. (US) | 1994-09-06 | — | — | US | disclosed |
| WO-1992009259-A1 | STIMULATION OF HAIR GROWTH WITH POTASSIUM CHANNEL OPENERS AND AN ANDROGEN RECEPTOR BLOCKER | THE UPJOHN COMPANY (US) | 1992-06-11 | — | — | WO | disclosed |
| US-5087640-A | Potassium channel openers; hypotensive agents, coronary vasodilators | KANEBO, LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| EP-0207606-A2 | Use of pinacidil as an antiasthma agent | ELI LILLY AND COMPANY (US) | 1987-01-07 | — | — | EP | disclosed |
| US-4617311-A | ADMINISTERING PINACIDIL | ELI LILLY AND COMPANY (US) | 1986-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012067-A1 | Modulation of Hypothalamic Atp-Sensitive Potassium Channels | PYGB, PC, KCNN3 | ABCC9 384/4885KCNJ11 18/4885CYP3A4 2037/4885 |
| US-20070026079-A1 | Intranasal administration of modulators of hypothalamic ATP-sensitive potassium channels | PC, LIPE, ATP5ME | ABCC9 482/4885KCNJ11 24/4885CYP3A4 3579/4885 |
| US-20100113379-A1 | cAMP DEPENDENT INDUCTION OF AUTOPHAGY | ATF4, TFEB, BECN1 | ABCC9 3634/4885KCNJ11 4444/4885CYP3A4 4671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.